Fig. 3: mutKRAS ctDNA measurements during the first 4 weeks of chemotherapy treatment. | British Journal of Cancer

Fig. 3: mutKRAS ctDNA measurements during the first 4 weeks of chemotherapy treatment.

From: Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma

Fig. 3

Longitudinal ctDNA measurements for cases are separated by whether ctDNA was detected or not detected at baseline (pre-treatment) and different colours identify survival status at 1 year (a) or RECIST response at week 8 (b). The grey-shaded area demonstrates the fractional abundance of ctDNA <1.

Back to article page